Top entities: Gossamer Bio, Hagens Berman, Reed Kathrein, Nasdaq-100, Merck & Co..

What category does this event fall under?

Business — classified as class action.

What is the sentiment of coverage?

Aggregate sentiment score: -70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This is an active story, last updated May 08, 2026. Coverage continues to evolve.

Business class action

Gossamer Bio Faces Securities Lawsuit

Q: When did this event occur?

First reported Apr 28, 2026; last updated May 08, 2026.

Q: What is the market impact?

Direct. The market is significantly impacted by the failure of Gossamer Bio's Phase 3 PROSERA study, leading to an 80% stock drop and a securities class action lawsuit.

Analysis based on 8 articles · First reported Apr 28, 2026 · Last updated May 08, 2026

Sentiment

-70

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

The market is significantly impacted by the failure of Gossamer Bio's Phase 3 PROSERA study, leading to an 80% stock drop and a securities class action lawsuit. This event highlights the risks associated with pharmaceutical research and development, potentially increasing investor scrutiny on similar biotech companies and their clinical trial disclosures.

Biotechnology Pharmaceuticals Legal Services

Event Summary

A securities class action lawsuit has been filed against Gossamer Bio and an executive, representing investors who purchased Gossamer Bio securities between June 16, 2025, and February 20, 2026. The lawsuit stems from Gossamer Bio's announcement on February 23, 2026, that its Phase 3 PROSERA study for pulmonary arterial hypertension (PAH) failed to meet its primary endpoint, causing an 80% decline in Gossamer Bio's stock price. The firm Hagens Berman is leading the investigation, focusing on whether Gossamer Bio misled investors about the trial design, including patient recruitment protocols and site-level monitoring, particularly concerning an 'outsized placebo response' in Americas. Furthermore, Gossamer Bio has not met the minimum share bid price for continued listing on Nasdaq-100 since February 24, 2026.

Entities Involved

stock

Gossamer Bio

Gossamer Bio is facing a securities class action lawsuit after its Phase 3 PROSERA study failed to meet its primary endpoint, causing an 80% drop in its stock price and potential delisting from Nasdaq-100. The lawsuit alleges that Gossamer Bio misled investors about the trial design.

Importance 100 Sentiment -90

priv

Hagens Berman

Hagens Berman is a national shareholder rights firm that initiated the securities class action lawsuit against Gossamer Bio and is investigating alleged violations of federal securities laws.

Importance 80 Sentiment 60

per

Reed Kathrein

Reed Kathrein is the Hagens Berman partner leading the firm's investigation into Gossamer Bio's alleged misleading disclosures.

Importance 40 Sentiment 50

index

Nasdaq-100

Gossamer Bio faces potential delisting from Nasdaq-100 Global Select Market due to not meeting the minimum share bid price requirement.

Importance 20 Sentiment 0

stock

Merck & Co.

Merck & Co. is mentioned as having a highly successful Phase 3 STELLAR study for treating PAH, which Gossamer Bio management cited in the past.

Importance 10 Sentiment 0

loc

Americas

Americas is identified as a region where Gossamer Bio's PROSERA study patients showed an outsized placebo response, materially diluting the treatment effect.

Importance 10 Sentiment 0

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard